Jump Financial’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-136,972
| Closed | -$2.95M | – | 1885 |
|
|
2025
Q4 | $2.95M | Sell |
136,972
-412,859
| -75% | -$8.02M | 0.04% | 538 |
|
|
2025
Q3 | $8.4M | Buy |
549,831
+410,877
| +296% | +$5.35M | 0.1% | 259 |
|
|
2025
Q2 | $1.23M | Buy |
+138,954
| New | +$1.22M | 0.01% | 893 |
|
|
2024
Q4 | – | Sell |
-36,182
| Closed | -$475K | – | 1636 |
|
|
2024
Q3 | $475K | Sell |
36,182
-10,118
| -22% | -$154K | 0.01% | 1126 |
|
|
2024
Q2 | $651K | Sell |
46,300
-79,700
| -63% | -$1.3M | 0.01% | 1019 |
|
|
2024
Q1 | $2.13M | Buy |
126,000
+106,088
| +533% | +$1.58M | 0.06% | 418 |
|
|
2023
Q4 | $281K | Sell |
19,912
-33,659
| -63% | -$395K | 0.01% | 1378 |
|
|
2023
Q3 | $552K | Buy |
+53,571
| New | +$717K | 0.02% | 972 |
|
|
2022
Q3 | – | Sell |
-56,300
| Closed | -$137K | – | 1577 |
|
|
2022
Q2 | $137K | Buy |
56,300
+25,100
| +80% | +$103K | 0.01% | 1388 |
|
|
2022
Q1 | $213K | Buy |
31,200
+14,397
| +86% | +$99K | 0.01% | 1267 |
|
|
2021
Q4 | $136K | Buy |
+16,803
| New | +$154K | 0.01% | 1179 |
|
|
2021
Q3 | – | Sell |
-13,712
| Closed | -$92K | – | 1095 |
|
|
2021
Q2 | $92K | Buy |
+13,712
| New | +$109K | 0.01% | 986 |
|
|
2021
Q1 | – | Sell |
-11,754
| Closed | -$79K | – | 935 |
|
|
2020
Q4 | $79K | Buy |
11,754
+1,063
| +10% | +$6.65K | 0.01% | 880 |
|
|
2020
Q3 | $54K | Buy |
+10,691
| New | +$77.8K | 0.01% | 721 |
|
Other funds holding AVDL
Jump Financial's AVDL Position: Q1 2026 in Review
Jump Financial sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 136,972 shares — an estimated $2.95M sold.
Jump Financial first reported a position in AVDL in Q3 2020 and held it in 14 quarters. The position peaked at $8.4M in Q3 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Jump Financial reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Jump Financial sold 136,972 Avadel Pharmaceuticals shares in Q1 2026, an estimated $2.95M.
- Jump Financial first reported a position in Avadel Pharmaceuticals in Q3 2020 and held it in 14 quarters.
- Jump Financial's Avadel Pharmaceuticals position peaked at $8.4M in Q3 2025.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.